Insmed reports positive 12-month OLE data for TPIP in PAH; sustained improvement across endpoints

INSMED Inc

6MWD improved +55.7m (TPIP continued) and +54.1m (placebo crossed) from baseline at Month 12.
NT-proBNP reduced ~60% in both groups; WHO Functional Class I/II achieved in ~80% of patients.
REVEAL Lite 2.0 score improved 2.0 points (TPIP continued) and 1.4 points (placebo crossed); ~65% low-risk.
TPIP well-tolerated with no new safety signals; most common TEAEs: headache (28.6%), cough (15.4%).
Phase 3 PALM-PAH trial initiated; topline Phase 2b results previously reported June 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.